CEL SCI CORP
10-Q/A, 1996-06-26
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ARIZONA INSTRUMENT CORP, 8-A12G, 1996-06-26
Next: CORTECH INC, 10-Q/A, 1996-06-26



8


                            PART II

Item 6.

     (a)    Exhibits

          FDS Schedule - EX-27.


                           SIGNATURES

Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the Registrant has duly caused this report to be signed  on
its behalf by the undersigned thereunto duly authorized.



                                   CEL-SCI Corporation

Date:_______________, 1996                        By:   Geert  R.
Kersten
                                   Chief Executive Officer*

*Also signing in the capacity of the Chief Accounting Officer and
Principal Financial Officer.



<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000725363
<NAME> CEL SCI CORPORATION
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1995
<PERIOD-END>                               MAR-31-1996
<CASH>                                      $3,803,786
<SECURITIES>                                   170,000
<RECEIVABLES>                                  221,254
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             4,437,852
<PP&E>                                         981,823
<DEPRECIATION>                                 740,239
<TOTAL-ASSETS>                               5,861,027
<CURRENT-LIABILITIES>                          301,159
<BONDS>                                      1,250,000
                                0
                                          0
<COMMON>                                        63,286
<OTHER-SE>                                  30,904,595
<TOTAL-LIABILITY-AND-EQUITY>                 5,861,027
<SALES>                                              0
<TOTAL-REVENUES>                                47,819
<CGS>                                                0
<TOTAL-COSTS>                                1,323,022
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,275,203)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,275,203)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,275,203)
<EPS-PRIMARY>                                   (0.21)
<EPS-DILUTED>                                   (0.21)
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission